529 related articles for article (PubMed ID: 22281991)
1. Serum ferritin levels and endocrinopathy in medically treated patients with β thalassemia major.
Belhoul KM; Bakir ML; Saned MS; Kadhim AM; Musallam KM; Taher AT
Ann Hematol; 2012 Jul; 91(7):1107-14. PubMed ID: 22281991
[TBL] [Abstract][Full Text] [Related]
2. Hypogonadism, diabetes mellitus, hypothyroidism, hypoparathyroidism: incidence and prevalence related to iron overload and chelation therapy in patients with thalassaemia major followed from 1980 to 2007 in the Ferrara Centre.
Gamberini MR; De Sanctis V; Gilli G
Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():158-69. PubMed ID: 19337172
[TBL] [Abstract][Full Text] [Related]
3. Endocrinopathies, metabolic disorders, and iron overload in major and intermedia thalassemia: serum ferritin as diagnostic and predictive marker associated with liver and cardiac T2* MRI assessment.
Chirico V; Rigoli L; Lacquaniti A; Salpietro V; Piraino B; Amorini M; Salpietro C; Arrigo T
Eur J Haematol; 2015 May; 94(5):404-12. PubMed ID: 25200112
[TBL] [Abstract][Full Text] [Related]
4. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
Daar S; Pathare AV
Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of iron overload complications among patients with b-thalassemia major treated at Dubai Thalassemia Centre.
Belhoul KM; Bakir ML; Kadhim AM; Dewedar HE; Eldin MS; Alkhaja FA
Ann Saudi Med; 2013; 33(1):18-21. PubMed ID: 23458935
[TBL] [Abstract][Full Text] [Related]
6. The impact of genotype on endocrine complications in thalassaemia major.
Skordis N; Michaelidou M; Savva SC; Ioannou Y; Rousounides A; Kleanthous M; Skordos G; Christou S
Eur J Haematol; 2006 Aug; 77(2):150-6. PubMed ID: 16800840
[TBL] [Abstract][Full Text] [Related]
7. Treatment and complications of thalassemia major in Guangxi, Southern China.
Yin XL; Wu ZK; He YY; Zhou TH; Zhou YL; Zhang XH
Pediatr Blood Cancer; 2011 Dec; 57(7):1174-8. PubMed ID: 21394896
[TBL] [Abstract][Full Text] [Related]
8. Serum ferritin level as a predictor of impaired growth and puberty in thalassemia major patients.
Shalitin S; Carmi D; Weintrob N; Phillip M; Miskin H; Kornreich L; Zilber R; Yaniv I; Tamary H
Eur J Haematol; 2005 Feb; 74(2):93-100. PubMed ID: 15654898
[TBL] [Abstract][Full Text] [Related]
9. Endocrinopathies in patients with transfusion-dependent beta-thalassemia.
Mehrvar A; Azarkeivan A; Faranoush M; Mehrvar N; Saberinedjad J; Ghorbani R; Vossough P
Pediatr Hematol Oncol; 2008; 25(3):187-94. PubMed ID: 18432501
[TBL] [Abstract][Full Text] [Related]
10. Correlation of iron overload and glomerular filtration rate estimated by cystatin C in patients with β-thalassemia major.
Al-Khabori M; Bhandari S; Al-Rasadi K; Mevada S; Al-Dhuhli H; Al-Kemyani N; Daar S
Hemoglobin; 2014; 38(5):365-8. PubMed ID: 25074643
[TBL] [Abstract][Full Text] [Related]
11. Non-transferrin-bound labile plasma iron and iron overload in sickle-cell disease: a comparative study between sickle-cell disease and beta-thalassemic patients.
Koren A; Fink D; Admoni O; Tennenbaum-Rakover Y; Levin C
Eur J Haematol; 2010 Jan; 84(1):72-8. PubMed ID: 19732137
[TBL] [Abstract][Full Text] [Related]
12. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major.
Farmaki K; Tzoumari I; Pappa C; Chouliaras G; Berdoukas V
Br J Haematol; 2010 Feb; 148(3):466-75. PubMed ID: 19912219
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of endocrine complications in beta-thalassaemia major in the Islamic Republic of Iran.
Karamifar H; Shahriari M; Sadjadian N
East Mediterr Health J; 2003; 9(1-2):55-60. PubMed ID: 15562733
[TBL] [Abstract][Full Text] [Related]
14. History of myocardial iron loading is a strong risk factor for diabetes mellitus and hypogonadism in adults with β thalassemia major.
Ang AL; Tzoulis P; Prescott E; Davis BA; Barnard M; Shah FT
Eur J Haematol; 2014 Mar; 92(3):229-36. PubMed ID: 24164584
[TBL] [Abstract][Full Text] [Related]
15. Endocrine complications in patients with Thalassaemia Major.
Toumba M; Sergis A; Kanaris C; Skordis N
Pediatr Endocrinol Rev; 2007 Dec; 5(2):642-8. PubMed ID: 18084158
[TBL] [Abstract][Full Text] [Related]
16. A randomized double-blind, placebo-controlled study of therapeutic effects of silymarin in β-thalassemia major patients receiving desferrioxamine.
Moayedi B; Gharagozloo M; Esmaeil N; Maracy MR; Hoorfar H; Jalaeikar M
Eur J Haematol; 2013 Mar; 90(3):202-9. PubMed ID: 23278124
[TBL] [Abstract][Full Text] [Related]
17. Pulmonary Functions in Children With Thalassemia Major.
Ozyoruk D; Misirlioglu ED
J Pediatr Hematol Oncol; 2015 Nov; 37(8):605-10. PubMed ID: 26422288
[TBL] [Abstract][Full Text] [Related]
18. Longitudinal changes of endocrine and bone disease in adults with β-thalassemia major receiving different iron chelators over 5 years.
Poggi M; Sorrentino F; Pugliese P; Smacchia MP; Daniele C; Equitani F; Terlizzi F; Guitarrini MR; Monti S; Maffei L; Losardo A; Pasin M; Toscano V
Ann Hematol; 2016 Apr; 95(5):757-63. PubMed ID: 26957357
[TBL] [Abstract][Full Text] [Related]
19. Hypoparathyroidism in transfusion-dependent patients with beta-thalassemia.
Chern JP; Lin KH
J Pediatr Hematol Oncol; 2002 May; 24(4):291-3. PubMed ID: 11972098
[TBL] [Abstract][Full Text] [Related]
20. Endocrinopathies in patients with thalassemias.
Al-Elq AH; Al-Saeed HH
Saudi Med J; 2004 Oct; 25(10):1347-51. PubMed ID: 15494799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
